Sight Sciences Q3 Revenue Tops Estimates at $24.9M, Gross Margin 86%
SGHT has more than doubled off its 52-week low of $3.378 on elevated volume (2.2× avg).
Summary
Sight Sciences posted Q3 revenue of $24.9M, beating the $23.5M IBES estimate. That follows Q2 revenue of $23.4M (+20% YoY), so the top line is holding its upward trend. Gross margin came in at 86% on $21.4M of gross profit, but operating expenses of $27.5M still left a $6.8M net loss. The company also raised its full-year 2026 revenue guidance to $92M–$93M. The revenue beat is the headline positive; the expense base remains the swing factor for how fast losses narrow.
At the time of this announcement, SGHT was trading at $9.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $533.3M. The 52-week trading range was $3.38 to $10.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.